Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Update: 2018-11-16

Description

Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.

Comments

In Channel

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

2019-03-0820:37

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

2019-03-0524:33

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

2018-12-2813:28

What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

2018-12-2108:58

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

2018-12-1109:58

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

2018-12-0909:53

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

2018-12-0406:39

The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

2018-12-0209:42

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

2018-11-1604:13

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

2018-11-1408:04

Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

2018-11-0807:22

IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

2018-11-0607:19

"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)

2018-09-0709:09

Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)

2018-09-0415:37

TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

2018-08-3103:40

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)

2018-08-2901:35

What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)

2018-08-2702:47

New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

2018-08-2403:03

Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)

2018-08-2202:03

Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)

2018-08-2001:08

00:00

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

#box-pro-ellipsis-176041673322644{-webkit-line-clamp:2;}Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)